Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Fluidigm Launches Low-Cost Assays for Gene Expression, SNP Genotyping and Target-Specific Primers for Next-Generation Sequencing

Published: Wednesday, May 11, 2011
Last Updated: Wednesday, May 11, 2011
Bookmark and Share
Company to disclose assay sequences to accelerate customer research.

Fluidigm Corporation has announced the availability of assays and primers optimized for the company’s integrated fluidic circuit technology. Fluidigm Assays and Target-specific Primers will provide customers with significantly lower costs than today’s standard solutions, at volumes appropriate for microfluidics, and flexible chemistries so that customers can easily create highly multiplexed panels using off-the-shelf and custom content focused on their particular research area.

As part of the program, Fluidigm will provide the assay primer locus sequences with every order.

The products are being marketed as DELTAgene™ Assays (gene expression), SNPtype™ Assays (SNP genotyping), and Access Array™ Target-specific Primers (target enrichment for next-generation sequencing). These products are available now.

“Due to our chemistry choice, our assays are priced substantially lower than labeled probe-based methods, so users can purchase hundreds of assays at a cost that is affordable. It has long been known that there are substantial benefits for researchers exploring multiple targets. In gene expression and genotyping studies, more targets provide better information and higher quality end results. The key was being able to achieve these results at a reasonable cost and rapid throughput. Fluidigm Assays provide that capability,” said Gajus Worthington, president and chief executive officer, Fluidigm.

Worthington continued, “In addition, our assay customers will receive the assay locus sequence from us on every order which will make it easier for the results to be MIQE compliant. This is something researchers have long sought and Fluidigm is committed to making our customers successful.”

MIQE (minimum information for publication of quantitative real-time PCR experiments) was designed to provide commonsense guidelines for enhancing the reproducibility and transparency of quantitative real-time PCR assays.

Key elements of Fluidigm’s offerings are:
• DELTAgene Assays for gene expression can be custom designed to any reference sequence. In addition, Fluidigm has a catalog of biologically grouped quantitative PCR assays that researchers can customize into panels.
• SNPtype Assays offer a low-cost SNP genotyping solution. Assays are made on-demand and are ready to meet high-throughput needs for a wide range of agricultural applications and confirmation of next-generation sequencing results.
• Access Array Target-specific Primers provide an easy way for customers to generate sequencer ready amplicons for next-generation sequencing. Currently, Fluidigm offers custom PCR-based primer design for human and mouse targeted resequencing.

Fluidigm provides sufficient volume of assay and primer solution to run hundreds of Fluidigm chips at costs substantially lower than traditional competitors offer. The company has simple-to-use protocols that save customers time and effort. This allows researchers to spend less time on assay development and more time gathering results and publishing quickly.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Revealing the Role of “Precocious” Dendritic Cells in Inflammatory Response
Discovery makes it possible for researchers to explore how these “precocious” cells escalate the body’s immune response when the body is under attack.
Monday, July 07, 2014
Singapore Single-Cell Research Centre Opens Door for Asian Biological Discoveries
Centre dedicated to diagnosis and treatment derived from single-cell exploration.
Monday, April 29, 2013
Fluidigm Announces $60 Million Public Offering of Common Stock
Company has closed the previously announced underwritten public offering of 4,209,000 shares of its common stock at a price to the public of $14.25 per share for gross proceeds of approximately $60 million.
Wednesday, August 22, 2012
Fluidigm Announces Unrestricted Sales into Prenatal Health
Fluidigm collaboration ends.
Tuesday, June 19, 2012
New Research Center to Focus on Mammalian Single Cell Genomics
New Center will feature a complete suite of Fluidigm single-cell tools, protocols and technologies.
Friday, June 15, 2012
Fluidigm Reports Financial Results for First Quarter 2012
Q1 total revenue up 26% compared to Q1 2011.
Monday, May 14, 2012
Leading Leukemia Lab Invests In Fluidigm Access Array™ and EP1™ Systems
Fluidigm Corporation has announced that MLL Munich Leukemia Laboratory (www.mll.com) has purchased Access Array™ and EP1™ Systems.
Tuesday, November 16, 2010
Research Newsletter for Biochip User Community
Fluidigm announces availability of the Fall 2010 edition of its community newsletter.
Tuesday, October 19, 2010
Fluidigm Europe Announces a new Technical Poster Describing its Access Array™ Chip Technology
New poster describes how Access Array™ chip technology has been used at NCI’s core facility to capture and sequence the entire EBV genome.
Friday, August 13, 2010
Modelling the Genetic Circuitry of Cell-to-Cell Communication
Stanford researchers used Fluidigm support instrumentation for analysis and modeling on how biological systems operate at the cellular level.
Thursday, July 15, 2010
Fluidigm Announces Availability of its Summer 2010 Edition of ‘IFC Application Hotspot’ E-newsletter
Issue includes two customer application studies, a recorded video interview with the GIS and a new single-cell gene expression protocol.
Friday, July 09, 2010
Fred Walder Joins Fluidigm as Chief Business Officer
Senior Executive from Fortune 500 company to lead business development and marketing for integrated fluidic circuit inventor.
Wednesday, June 30, 2010
Pathway-Focused Gene Expression Panels Validated for Real-time PCR
Fluidigm and SABiosciences team up to create gene expression panels validated for real-time PCR analysis on the Fluidigm BioMark™ System.
Thursday, April 08, 2010
Fluidigm and Bayer Cropscience Enter Global Agreement for Marker-Assisted Breeding and Quality Control
Fluidigm to supply integrated fluidic circuits and instrumentation to Bayer CropScience's global operations under the multi-year agreement.
Friday, February 19, 2010
Fluidigm and Bayer Cropscience Enter Global Agreement for Marker-Assisted Breeding and Quality Control
Multi-Year Supply Agreement to Drive High-Quality Seed Supply
Thursday, January 28, 2010
Scientific News
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
'Kidney on a Chip' Facilitates Safer Drug Dosing
University of Michigan researchers have used a "kidney on a chip" device to mimic the flow of medication through human kidneys and measure its effect on kidney cells.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Experimental Therapy For Brain Cancer Could Prevent Drug Resistance
Information from penny-sized microfluidic chips allowed researchers to anticipate resistance to cancer treatment.
3D Printing of Lego Fluidics
Study shows how 3D printing can open up microfluidic technology to a wider audience.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!